Hudson Bay Capital Management
EWTX icon

Hudson Bay Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Hudson Bay Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$1.1M – 1463
2025
Q1 		$1.1M Buy
+50,000
New +$1.31M ﹤0.01% 908

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Hudson Bay Capital Management's EWTX Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Edgewise Therapeutics (EWTX) in Q1 2026: 12,930 shares worth $407K. The stake represents ﹤0.01% of the portfolio and ranks #999 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in EWTX as recently as Q3 2024.

Hudson Bay Capital Management first reported a position in EWTX in Q4 2023 and has held it in 3 quarters since. The position peaked at $13M in Q4 2023. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Hudson Bay Capital Management held 12,930 shares of Edgewise Therapeutics worth $407K as of Q1 2026.
  • Edgewise Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #999 holding.
  • Hudson Bay Capital Management first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • Hudson Bay Capital Management's Edgewise Therapeutics position peaked at $13M in Q4 2023.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.